Startup utilizing Duke technology targets point-of-care diagnostic care
A startup company based on technology licensed from Duke University is looking to disrupt a $1 billion portion of the point-of-care diagnostics industry by harnessing a feature formerly considered a defect—surface roughness. Many diagnostic devices that capture biomarkers suspended in blood rely on fluorescent molecules for their detection. While this method is popular in commercially used diagnostics, there are alternative and potentially more powerful methods. These methods, however, are currently restrained to laboratory settings. One such method uses piezoelectric materials—materials that create an electric current when strained or vibrated and, conversely, vibrate when connected to an alternating current. Because...
Read More
